{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,6]],"date-time":"2026-10-06T00:14:25Z","timestamp":1791245665579,"version":"4.1.0"},"reference-count":19,"publisher":"Walter de Gruyter GmbH","issue":"1","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2025,1,31]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec id=\"j_jbcpp-2024-0140_abs_001\">\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>Metabolic-Associated Steatohepatitis-Related Liver Disease (MASLD) and, its progressive form, Metabolic-Associated Steatohepatitis (MASH) pose significant global health challenges. Current therapeutic strategies targeting metabolic abnormalities have shown promise but lack specificity for the liver. Thyroid hormones, particularly thyroid hormone receptor beta (THR-\u03b2) agonists like resmetirom, offer a targeted approach to liver-related pathways.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2024-0140_abs_002\">\n                    <jats:title>Content<\/jats:title>\n                    <jats:p>A network meta-analysis (NMA) comparing different doses of resmetirom to placebo for MASLD and MASH was conducted. PubMed, Scopus, Cochrane, and Web\u00a0of Science were searched for relevant randomized controlled trials (RCTs). Efficacy outcomes included histological, radiological, and biochemical parameters, while safety outcomes comprised adverse events and treatment discontinuation.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2024-0140_abs_003\">\n                    <jats:title>Summary<\/jats:title>\n                    <jats:p>Resmetirom demonstrated dose-dependent efficacy in histological and radiological assessments, with the 100\u202fmg dose showing superior MASH resolution and hepatic fat reduction. Biochemical markers indicated improved liver function with resmetirom treatment. However, adverse events, particularly diarrhea and nausea, were more prevalent in the resmetirom group, leading to higher treatment discontinuation rates.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"j_jbcpp-2024-0140_abs_004\">\n                    <jats:title>Outlook<\/jats:title>\n                    <jats:p>Resmetirom shows promise as a therapeutic option for MASLD and MASH management, with significant improvements in liver health parameters. However, safety concerns warrant careful monitoring in clinical practice. Further research is needed to optimize its long-term safety and efficacy.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1515\/jbcpp-2024-0140","type":"journal-article","created":{"date-parts":[[2025,1,8]],"date-time":"2025-01-08T09:03:42Z","timestamp":1736327022000},"page":"3-11","source":"Crossref","is-referenced-by-count":5,"title":["Efficacy and safety of resmetirom in MASLD and MASH: network meta-analysis of randomized clinical trials"],"prefix":"10.1515","volume":"36","author":[{"given":"Hazem","family":"Ayesh","sequence":"first","affiliation":[{"name":"Deaconess Health System , Evansville , IN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Azizullah","family":"Beran","sequence":"additional","affiliation":[{"name":"Division of Gastroenterology and Hepatology , Indiana University School of Medicine , Indianapolis , IN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sajida","family":"Suhail","sequence":"additional","affiliation":[{"name":"Gene Medical Labs , Gaza , Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suhail","family":"Ayesh","sequence":"additional","affiliation":[{"name":"Gene Medical Labs , Gaza , Palestine"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin","family":"Niswender","sequence":"additional","affiliation":[{"name":"Division of Diabetes, Endocrinology, and Metabolism, Department of Medicine , Vanderbilt University Medical Center , Nashville , TN , USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2025,1,9]]},"reference":[{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_001","doi-asserted-by":"crossref","unstructured":"Kabarra, K, Golabi, P, Younossi, ZM. Nonalcoholic steatohepatitis: global impact and clinical consequences. Endocr Connect 2021;10:R240\u2013r7. https:\/\/doi.org\/10.1530\/ec-21-0048.","DOI":"10.1530\/EC-21-0048"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_002","doi-asserted-by":"crossref","unstructured":"Lazure, P, Tomlinson, JW, Kowdley, KV, Magni, P, Santos, RD, Jacobs, G, et al.. Clinical practice gaps and challenges in non-alcoholic steatohepatitis care: an international physician needs assessment. Liver Int 2022;42:1772\u201382. https:\/\/doi.org\/10.1111\/liv.15324.","DOI":"10.1111\/liv.15324"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_003","doi-asserted-by":"crossref","unstructured":"Jeeyavudeen, MS, Khan, SKA, Fouda, S, Pappachan, JM. Management of metabolic-associated fatty liver disease: the diabetology perspective. World J Gastroenterol 2023;29:126\u201343. https:\/\/doi.org\/10.3748\/wjg.v29.i1.126.","DOI":"10.3748\/wjg.v29.i1.126"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_004","doi-asserted-by":"crossref","unstructured":"Lee, HA, Kim, HY. Therapeutic mechanisms and clinical effects of glucagon-like peptide 1 receptor agonists in nonalcoholic fatty liver disease. Int J Mol Sci 2023;24:9324. https:\/\/doi.org\/10.3390\/ijms24119324.","DOI":"10.3390\/ijms24119324"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_005","doi-asserted-by":"crossref","unstructured":"Li, R, Zhou, L, Chen, C, Han, X, Gao, M, Cheng, X, et al.. Sensitivity to thyroid hormones is associated with advanced fibrosis in euthyroid patients with non-alcoholic fatty liver disease: a cross-sectional study. Dig Liver Dis 2023;55:254\u201361. https:\/\/doi.org\/10.1016\/j.dld.2022.06.021.","DOI":"10.1016\/j.dld.2022.06.021"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_006","doi-asserted-by":"crossref","unstructured":"Sinha, RA, Singh, BK, Yen, PM. Direct effects of thyroid hormones on hepatic lipid metabolism. Nat Rev Endocrinol 2018;14:259\u201369. https:\/\/doi.org\/10.1038\/nrendo.2018.10.","DOI":"10.1038\/nrendo.2018.10"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_007","doi-asserted-by":"crossref","unstructured":"Karim, G, Bansal, MB. Resmetirom: an orally administered, smallmolecule, liver-directed, \u03b2-selective THR agonist for the treatment of non-alcoholic fatty liver disease and non-alcoholic steatohepatitis. touchREV Endocrinol 2023;19:60\u201370. https:\/\/doi.org\/10.17925\/ee.2023.19.1.60.","DOI":"10.17925\/EE.2023.19.1.60"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_008","doi-asserted-by":"crossref","unstructured":"Kowalik, MA, Columbano, A, Perra, A. Thyroid hormones, thyromimetics and their metabolites in the treatment of liver disease. Front Endocrinol 2018;9:382. https:\/\/doi.org\/10.3389\/fendo.2018.00382.","DOI":"10.3389\/fendo.2018.00382"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_009","unstructured":"Ayesh, H, Beran, A, Suhail, S, Niswender, K. Efficacy and safety of Resmetirom in nonalcoholic fatty liver disease and nonalcoholic steatohepatitis: network meta-analysis protocol. OSF Registries; 2024. Available from: https:\/\/doi.org\/10.17605\/OSF.IO\/Z9CQA."},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_010","doi-asserted-by":"crossref","unstructured":"Page, MJ, McKenzie, JE, Bossuyt, PM, Boutron, I, Hoffmann, TC, Mulrow, CD, et al.. The PRISMA 2020 statement: an updated guideline for reporting\u00a0systematic reviews. BMJ 2021;372. https:\/\/doi.org\/10.1136\/bmj.n71.","DOI":"10.1136\/bmj.n71"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_011","doi-asserted-by":"crossref","unstructured":"Altman, DG, Bland, JM. Standard deviations and standard errors. Br Med J 2005;331:903. https:\/\/doi.org\/10.1136\/bmj.331.7521.903.","DOI":"10.1136\/bmj.331.7521.903"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_012","doi-asserted-by":"crossref","unstructured":"Wan, X, Wang, W, Liu, J, Tong, T. Estimating the sample mean and standard deviation from the sample size, median, range and\/or interquartile range. BMC Med Res Methodol 2014;14:135. https:\/\/doi.org\/10.1186\/1471-2288-14-135.","DOI":"10.1186\/1471-2288-14-135"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_013","doi-asserted-by":"crossref","unstructured":"Sterne, JAC, Savovi\u0107, J, Page, MJ, Elbers, RG, Blencowe, NS, Boutron, I, et al.. RoB 2: a revised tool for assessing risk of bias in randomised trials. BMJ 2019;366. https:\/\/doi.org\/10.1136\/bmj.l4898.","DOI":"10.1136\/bmj.l4898"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_014","doi-asserted-by":"crossref","unstructured":"Jansen, JP, Fleurence, R, Devine, B, Itzler, R, Barrett, A, Hawkins, N, et al.. Interpreting indirect treatment comparisons and network meta-analysis for health-care decision making: report of the ISPOR Task Force on Indirect Treatment Comparisons Good Research Practices: part 1. Value Health 2011;14:417\u201328. https:\/\/doi.org\/10.1016\/j.jval.2011.04.002.","DOI":"10.1016\/j.jval.2011.04.002"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_015","doi-asserted-by":"crossref","unstructured":"Rhodes, KM, Turner, RM, Higgins, JP. Predictive distributions were developed for the extent of heterogeneity in meta-analyses of continuous outcome data. J Clin Epidemiol 2015;68:52\u201360. https:\/\/doi.org\/10.1016\/j.jclinepi.2014.08.012.","DOI":"10.1016\/j.jclinepi.2014.08.012"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_016","doi-asserted-by":"crossref","unstructured":"Nikolakopoulou, A, Higgins, JPT, Papakonstantinou, T, Chaimani, A, Del Giovane, C, Egger, M, et al.. CINeMA: an approach for assessing confidence in the results of a network meta-analysis. PLoS Med 2020;17. https:\/\/doi.org\/10.1371\/journal.pmed.1003082.","DOI":"10.1371\/journal.pmed.1003082"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_017","doi-asserted-by":"crossref","unstructured":"Harrison, SA, Bashir, MR, Guy, CD, Zhou, R, Moylan, CA, Frias, JP, et al.. Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. Lancet 2019;394:2012\u201324. https:\/\/doi.org\/10.1016\/s0140-6736(19)32517-6.","DOI":"10.1016\/S0140-6736(19)32517-6"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_018","doi-asserted-by":"crossref","unstructured":"Harrison, SA, Bedossa, P, Guy, CD, Schattenberg, JM, Loomba, R, Taub, R, et al.. A phase 3, randomized, controlled trial of Resmetirom in MASH with liver fibrosis. N Engl J Med 2024;390:497\u2013509. https:\/\/doi.org\/10.1056\/nejmoa2309000.","DOI":"10.1056\/NEJMoa2309000"},{"key":"2025121209195689848_j_jbcpp-2024-0140_ref_019","doi-asserted-by":"crossref","unstructured":"Harrison, SA, Taub, R, Neff, GW, Lucas, KJ, Labriola, D, Moussa, SE, et al.. Resmetirom for nonalcoholic fatty liver disease: a randomized, double-blind, placebo-controlled phase 3 trial. Nat Med 2023;29:2919\u201328. https:\/\/doi.org\/10.1038\/s41591-023-02603-1.","DOI":"10.1038\/s41591-023-02603-1"}],"container-title":["Journal of Basic and Clinical Physiology and Pharmacology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2024-0140\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2024-0140\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,12,12]],"date-time":"2025-12-12T12:10:16Z","timestamp":1765541416000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyterbrill.com\/document\/doi\/10.1515\/jbcpp-2024-0140\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1,1]]},"references-count":19,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12,13]]},"published-print":{"date-parts":[[2025,1,31]]}},"alternative-id":["10.1515\/jbcpp-2024-0140"],"URL":"https:\/\/doi.org\/10.1515\/jbcpp-2024-0140","relation":{},"ISSN":["2191-0286"],"issn-type":[{"value":"2191-0286","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,1,1]]}}}